Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597729 | 0.93 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL598076 | 0.92 | CYSLTR2 (0.73) | CYSLTR2CYSLTR1 | |
| SCHEMBL598258 | 0.91 | CYSLTR2 (0.85) | CYSLTR2CYSLTR1 | |
| SCHEMBL598098 | 0.91 | CYSLTR2 (0.85) | CYSLTR2CYSLTR1 | |
| SCHEMBL597855 | 0.91 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL598774 | 0.91 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1 | |
| SCHEMBL597467 | 0.90 | CYSLTR2 (0.79) | CYSLTR2CYSLTR1 | |
| Lysine SCHEMBL599536 | 0.90 | CYSLTR2 (0.73) | CYSLTR2CYSLTR1 | |
| Lysine SCHEMBL599535 | 0.90 | CYSLTR2 (0.73) | CYSLTR2CYSLTR1 | |
| SCHEMBL598035 | 0.89 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598223-B2 | Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | claimed |
| EP-2583964-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-24 | — | — | EP | claimed |
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | claimed |
| EP-2206698-B1 | Ethynylindole compounds | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | claimed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | claimed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | claimed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | claimed |
| EP-2583964-B1 | NEW CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO PHARMACEUTICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-8598223-B2 | Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2583964-A4 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO PHARMACEUTICAL CO (JP) | 2013-11-20 | — | — | EP | disclosed |
| CN-103080085-A | 4,4 ' - [ 4-fluoro-7- ({4- [4- (3-fluoro-2-methylphenyl) butoxy ] phenyl } ethynyl) -2-methyl-1H-indole-1, 3-diyl ] dibutanoic acid, 4 ' - [ 2-methyl-7- ({4- [4- (pentafluorophenyl) butoxy ] phenyl } ethynyl) -1H-indole-1, 3-diyl ] dibutanoic acid and 4,4 ' - [ 4-fluoro-2-methyl-7 | ONO PHARMACEUTICAL CO | 2013-05-01 | — | — | CN | disclosed |
| EP-2583964-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-2583964-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | disclosed |
| WO-2011162222-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | 小野薬品工業株式会社 (JP) | 2011-12-29 | — | — | WO | disclosed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | IDO1, HTR3C, HTR5A | CYSLTR2 3247/4885CYSLTR1 2772/4885 |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.